Mazdutide, a once-weekly injectable prescription medication modeled on a natural gut hormone, is approved in China for weight management and type 2 diabetes. Evidence is strong for substantial weight loss that grows with dose, and for lower blood sugar and blood fats; effects on heart attacks, strokes, deaths or aging are untested. Digestive side effects are common, and nearly all data come from its two developers. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; track percentage change from own baseline | Primary effect |
| HbA1c | Below 7.0% in type 2 diabetes | Expected to change; low values with insulin or sulfonylureas flag hypoglycemia risk |
| Fasting glucose | 70–99 mg/dL | Hypoglycemia safety check; expected to change |
| Lipid panel (LDL, HDL, triglycerides) | No established target; track change from own baseline | LDL and triglycerides fall; HDL may fall |
| ALT and AST | 7–55 U/L for ALT, 8–48 U/L for AST | Expected to fall with liver fat; a rise is a safety check |
| Liver fat (MRI-PDFF) | Below 5% | Expected to change |
| Serum uric acid | 3.5–7.2 mg/dL | Expected to change |
| Lipase and amylase | Lipase 13–60 U/L, amylase 40–140 U/L | Pancreatitis safety check |
| Creatinine and eGFR | Creatinine 0.7–1.3 mg/dL (men), 0.6–1.1 mg/dL (women); eGFR: track change from own baseline | Kidney injury safety check |
| Resting heart rate | 60–100 beats/min | Heart-rate rise safety check |
| Lean and fat mass (DXA) | No established target; track lean mass change from own baseline | Fat and lean mass fall |
Cadence: Baseline assessment before starting (retinal examination added in diabetes); weight and resting heart rate weekly during titration; symptoms and glucose (if diabetic) at each dose step; labs at 12 weeks, then every 3–6 months; liver fat imaging and DXA at 6–12 months, then yearly